Lumos Pharma, Inc. (LUMO): Price and Financial Metrics

Lumos Pharma, Inc. (LUMO): $3.03

0.02 (-0.66%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add LUMO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#195 of 347

in industry

LUMO Price/Volume Stats

Current price $3.03 52-week high $4.55
Prev. close $3.05 52-week low $2.63
Day low $2.95 Volume 10,600
Day high $3.09 Avg. volume 21,993
50-day MA $2.99 Dividend yield N/A
200-day MA $3.30 Market Cap 23.98M

LUMO Stock Price Chart Interactive Chart >

LUMO Stock Summary

  • LUMOS PHARMA INC's market capitalization of $24,218,621 is ahead of just 9.63% of US-listed equities.
  • The ratio of debt to operating expenses for LUMOS PHARMA INC is higher than it is for about just 4.34% of US stocks.
  • LUMO's price/sales ratio is 13.94; that's higher than the P/S ratio of 92.18% of US stocks.
  • If you're looking for stocks that are quantitatively similar to LUMOS PHARMA INC, a group of peers worth examining would be PALI, OGEN, TDUP, MEIP, and XBIO.
  • Visit LUMO's SEC page to see the company's official filings. To visit the company's web site, go to www.lumos-pharma.com.

LUMO Valuation Summary

  • LUMO's EV/EBIT ratio is 0.3; this is 97.95% lower than that of the median Healthcare stock.
  • LUMO's EV/EBIT ratio has moved up 8 over the prior 148 months.

Below are key valuation metrics over time for LUMO.

Stock Date P/S P/B P/E EV/EBIT
LUMO 2023-12-29 14.5 0.7 -0.8 0.3
LUMO 2023-12-28 14.4 0.7 -0.8 0.3
LUMO 2023-12-27 14.1 0.7 -0.7 0.3
LUMO 2023-12-26 13.9 0.7 -0.7 0.3
LUMO 2023-12-22 13.9 0.7 -0.7 0.3
LUMO 2023-12-21 13.9 0.7 -0.7 0.3

LUMO Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 9.4%.
  • Its year over year revenue growth rate is now at 131.97%.
  • Its 2 year price growth rate is now at -43.6%.
LUMO's revenue has moved up $295,000 over the prior 33 months.

The table below shows LUMO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.231 -26.625 -28.456
2022-06-30 0.734 -28.145 -28.693
2022-03-31 0.341 -27.269 -29.519
2021-12-31 0.23 -29.648 -30.43
2021-09-30 0.05 -30.8 -27.204
2021-06-30 0.124 -23.368 -17.951

LUMO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LUMO has a Quality Grade of D, ranking ahead of 21.86% of graded US stocks.
  • LUMO's asset turnover comes in at 0.001 -- ranking 434th of 681 Pharmaceutical Products stocks.
  • INVA, RETA, and SUPN are the stocks whose asset turnover ratios are most correlated with LUMO.

The table below shows LUMO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.001 1 -1.992
2021-03-31 0.001 1 -0.861
2020-12-31 0.001 1 -0.498
2020-09-30 0.004 1 -0.644
2020-06-30 0.005 1 -1.373
2020-03-31 0.007 1 -2.610

LUMO Price Target

For more insight on analysts targets of LUMO, see our LUMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.00 Average Broker Recommendation 1.42 (Moderate Buy)

Lumos Pharma, Inc. (LUMO) Company Bio


Lumos Pharma, Inc. operates as a biopharmaceutical company. The Company discovers, develops, and commercializes therapeutics for patients and families living with rare diseases. Lumos Pharma operates worldwide.


LUMO Latest News Stream


Event/Time News Detail
Loading, please wait...

LUMO Latest Social Stream


Loading social stream, please wait...

View Full LUMO Social Stream

Latest LUMO News From Around the Web

Below are the latest news stories about LUMOS PHARMA INC that investors may wish to consider to help them evaluate LUMO as an investment opportunity.

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

Webinar to be Held December 6, 2023 at 1:30pm ESTAUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail. Management will be joined by three esteemed thought leaders in th

Yahoo | November 21, 2023

Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November

AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference being held November 28th – 30th in New York City. Lumos Pharma management will present and host one-on-one meetings at the conference. Piper Sandler 35th Annual Healthcare Conference: November 28th – 30th Title:Lumos Pharma Fi

Yahoo | November 20, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones.

William White on InvestorPlace | November 8, 2023

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 – -- OraGrowtH210 Trial Results Show LUM-201 Dose of 1.6 mg/kg Achieves AHVs of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Consistent with Historical Growth Rates for Moderate PGHD Population – -- OraGrowtH212 Data Confirm Unique Pulsatile Mechanism of Action of LUM-201and Demonstrate Closer to Normal Physiological Growth Hormone Levels

Yahoo | November 7, 2023

Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 6 & 12 mo AHV ANCOVA Model Terms: treatment, Age at dose 1, Sex, Baseline HT SDS, Baseline BMI SDS, Baseline IGF-1 SDS, LUM-201 PEM, Baseline BA Delay, HT SDS-MPH SDS Bars represent Least Squares Mean (LSM), Error bars represent the Standard Error of LSM OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth

Yahoo | November 7, 2023

Read More 'LUMO' Stories Here

LUMO Price Returns

1-mo -0.98%
3-mo 4.48%
6-mo 3.77%
1-year -14.16%
3-year -83.73%
5-year -77.40%
YTD -4.72%
2023 -11.91%
2022 -47.91%
2021 -80.59%
2020 56.83%
2019 66.45%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!